ORIGINAL PAPER
Serum level of osteoprotegerin in patients with Parkinson’s disease:
a preliminary study
1
Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Orłowski Hospital, Warsaw, Poland
2
Department of Immunology, Faculty of Biology, University of Warsaw, Warsaw, Poland
Submission date: 2023-09-14
Final revision date: 2023-10-30
Acceptance date: 2023-12-05
Publication date: 2024-03-28
Corresponding author
Małgorzata Michałowska
Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Orłowski Hospital, Warsaw, Poland
Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Orłowski Hospital, Warsaw, Poland
Medical Studies 2024;40(1):33-37
KEYWORDS
TOPICS
ABSTRACT
Introduction::
Osteoprotegerin (OPG) has recently been suggested to be involved in the pathophysiology of Parkinson’s disease (PD).
Aim of the research::
To compare serum OPG levels in PD patients versus controls with mild headache or back pain (CG1) and acute ischaemic stroke (CG2) and evaluate the relationship between serum OPG level and 1) PD duration, 2) parathyroid hormone (PTH), vitamin D [25(OH)D], total calcium and 3) serum total cholesterol (TC), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglyceride levels.
Material and methods::
In the included 45 PD patients – 20 with initial PD (iPD) and 25 with advanced PD (aPD) and 50 controls (20 CG1, 30 CG2) – we measured serum OPG levels using a sandwich enzyme-linked immunosorbent assay and analysed data applying Student’s t, Mann-Whitney, c2 tests, Pearson’s correlation and linear regression analysis.
Results::
OPG serum level was lower in iPD compared to CG2 subjects (p = 0.026). OPG level depended on the duration of PD (p < 0.01) and TC level (p < 0.03) in PD patients, on 25(OH)D level (p < 0.04) in CG1 and on TC (p < 0.05) and PTH (p < 0.01) levels in CG2.
Conclusions::
Our results indicate that serum OPG level increases with PD duration and is associated with serum TC level in PD and ischaemic stroke patients.
Osteoprotegerin (OPG) has recently been suggested to be involved in the pathophysiology of Parkinson’s disease (PD).
Aim of the research::
To compare serum OPG levels in PD patients versus controls with mild headache or back pain (CG1) and acute ischaemic stroke (CG2) and evaluate the relationship between serum OPG level and 1) PD duration, 2) parathyroid hormone (PTH), vitamin D [25(OH)D], total calcium and 3) serum total cholesterol (TC), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglyceride levels.
Material and methods::
In the included 45 PD patients – 20 with initial PD (iPD) and 25 with advanced PD (aPD) and 50 controls (20 CG1, 30 CG2) – we measured serum OPG levels using a sandwich enzyme-linked immunosorbent assay and analysed data applying Student’s t, Mann-Whitney, c2 tests, Pearson’s correlation and linear regression analysis.
Results::
OPG serum level was lower in iPD compared to CG2 subjects (p = 0.026). OPG level depended on the duration of PD (p < 0.01) and TC level (p < 0.03) in PD patients, on 25(OH)D level (p < 0.04) in CG1 and on TC (p < 0.05) and PTH (p < 0.01) levels in CG2.
Conclusions::
Our results indicate that serum OPG level increases with PD duration and is associated with serum TC level in PD and ischaemic stroke patients.
REFERENCES (23)
1.
Baud’huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M, Redini F, Heymann MF, Heymann D. Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev 2013; 24: 401-409.
2.
Jensen JK, Ueland T, Atar D, Gullestad L, Mickley H, Aukrust P, Januzzi JL. Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med 2010; 267: 410-417.
3.
Glasnović A, O’Mara N, Kovačić N, Grčević D, Gajović S. RANK/RANKL/OPG signaling in the brain: a systematic review of the literature. Front Neurol 2020; 11: 590480.
4.
Lin Y, Zhou M, Dai W, Guo W, Qiu J, Zhang Z, Mo M, Ding L, Ye P, Wu Y, Zhu X, Wu Z, Xu P, Xiang C. Bone-derived factors as potential biomarkers for Parkinson’s disease. Front Aging Neurosci 2021; 13: 634213.
5.
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halli- day G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30: 1591-1601.
6.
Aldred J, Anca-Herschkovitsch M, Antonini A, Bajenaru O, Bergmann L, Bourgeois P, Cubo E, Davis TL, Iansek R, Kovács N, Kukreja P, Onuk K, Pontieri FE, Robieson W, Siddiqui MS, Simu M, Standaert DG, Chaudhuri KR. Application of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBE. Neurodegener Dis Manag 2020; 10: 309-323.
7.
Sacco RL, Kasner SE, Broderick JP, Caplan LR, Con- nors JJB, Culebras A, Elkind MSV, George MG, Ham- dan AD, Higashida RT, Hoh BL, Janis LS, Kase CS, Kleindorfer DO, Lee JM, Moseley ME, Peterson ED, Turan TN, Valderrama AL, Vinters HV; American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism. An update definition of stroke for the 21st century. Stroke 2013; 44: 2064-2089.
8.
Lequin RM. Enzyme Immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem 2005; 51: 2415-2418.
9.
Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney Jr JF, Rong J, Corey D, Hoffmann U, Fox CS, Vasan RS, Benjamin EJ, O’Donnel CJ, Kathiresan S. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010; 30: 1849-1854.
10.
Ghaffari S, Yaghoubi A, Baghernejad R, Sepehrvand N, Sokhanvar S, Haghjou AG. The value of serum osteoprotegerin levels in patients with angina like chest pain undergoing diagnostic coronary angiography. Cardiol J 2013; 20: 261-267.
11.
Özkalaycı F, Gülmez Ö, Uğur-Altun B, Pandi-Perumal SR, Altun A. The role of osteoprotegerin as a cardioprotective versus reactive inflammatory marker: the chicken or the egg paradox. Balkan Med J 2018; 35: 225-232.
12.
Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180.
13.
Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E, Tugrul A. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res 2007; 120: 511-516.
14.
Zhu Z, Guo D, Zhang K, Yang P, Jia Y, Shi M, Peng Y, Chen J, Wang A, Xu T, Zhang Y, He J. Osteoprotegerin and ischemic stroke prognosis: a prospective multicenter study and mendelian randomization analysis. Stroke 2023; 54: 509-517.
15.
Park MS, Chang Y, Kim KH, Park JH, Song TJ. Plasma osteoprotegerin levels are associated with the presence and burden of cerebral small vessel disease in patients with acute ischemic stroke. Clin Neurol Neurosurg 2021; 210: 107010.
16.
Kichev A, Rousset CI, Baburamani AA, Levison SW, Wood TL, Gressens P, Thornton C, Hagberg H. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling and cell death in the immature central nervous system after hypoxia-ischemia and inflammation. J Biol Chem 2014; 289: 9430-9439.
17.
Shimamura M, Nakagami H, Osako MK, Kurinami H, Koriyama H, Zhengda P, Tomioka H, Tenma A, Wakayama K, Morishita R. OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice. Proc Natl Acad Sci USA 2014; 111: 8191-8196.
18.
Sakai S, Shichita T. Inflammation and neural repair after ischemic brain injury. Neurochem Int 2019; 130: 104316.
19.
Alrafiah A, Al-Ofi E, Obaid MT, Alsomali N. Assessment of the levels of level of biomarkers of bone matrix glycoproteins and inflammatory cytokines from Saudi Parkinson patients. Biomed Res Int 2019; 2019: 2690205.
20.
Zhao Y, Shen L, Ji HF. Osteoporosis risk and bone mineral density levels in patients with Parkinson’s disease: a meta- nalysis. Bone 2013; 52: 498-505.
21.
Gannagé-Yared MH, Fares F, Semaan M, Khalife S, Jambart S. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006; 64: 652-658.
22.
Gannagé-Yared MH, Yaghi C, Habre B, Khalife S, Noun R, Germanos-Haddad M, Trak-Smayra V. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol 2008; 158: 353-359.
23.
Oh ES, Rhee EJ, Oh KW, Lee WY Baek KH, Yoon KH, Kang MI, Yun EJ, Park CY, Choi MG, Yoo HJ, Park SW. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism 2005; 54: 49-54.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
